Comparative Pharmacology
Head-to-head clinical analysis: E MYCIN versus E MYCIN E.
Peer-Reviewed Evidence
Head-to-head clinical analysis: E MYCIN versus E MYCIN E.
E-MYCIN vs E-MYCIN E
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by blocking the translocation of peptidyl-tRNA. It may also act as a motilin receptor agonist, enhancing gastrointestinal motility.
Erythromycin binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by blocking the translocation of peptide chains.
250-500 mg orally every 6 hours or 500 mg every 12 hours; maximum 4 g/day.
250-500 mg orally every 6 hours or 333-500 mg every 8 hours; maximum 4 g/day.
None Documented
None Documented
1.5-2 hours in adults with normal renal function; prolonged to 4-6 hours in severe hepatic impairment; no significant change in renal impairment due to minimal renal clearance.
Terminal elimination half-life is 1.5-3 hours in adults; prolonged to 4-6 hours in neonates and patients with hepatic impairment.
Primarily hepatic metabolism and biliary excretion with significant enterohepatic circulation; approximately 2-15% excreted unchanged in urine; 10-40% excreted in feces via bile; less than 1% eliminated as unchanged drug in feces from unabsorbed drug.
Primarily excreted unchanged in urine (70-80%) via glomerular filtration and tubular secretion; 15-20% excreted in feces via biliary elimination.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic